Company Lobe Sciences Ltd.

LOBE

CA53946V2066

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Chiffre d''affaires - Rate of surprise

Sector Alternative Medicine

Delayed Canadian Securities Exchange Other stock markets 03:59:31 2024-04-23 pm EDT			5-day change	1st Jan Change
0.02 ^CAD	0.00%		0.00%	-20.00%

Feb. 15	Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	CI
2023	Lobe Sciences Provides Update on L-130 Clinical Program	MT

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.

CAD in Million	2022	Weight	2023	Weight	Delta
Altemia 100.0 %	-	-	1	100.0 %	-

CAD in Million	2022	Weight	2023	Weight	Delta
Canada 100.0 %	0	nan %	1	100.0 %	-

Managers	Title	Age	Since
Philip Young CEO	Chief Executive Officer	66	21-01-14
Mathew Lee DFI	Director of Finance/CFO	40	23-09-17
Maghsoud Dariani CTO	Chief Tech/Sci/R&D Officer	-	20-07-20
Baxter Phillips COO	Chief Operating Officer	48	22-10-02
Frederick Sancilio CTO	Chief Tech/Sci/R&D Officer	74	-
Sandra Dosdall AUD	Comptroller/Controller/Auditor	55	-

Members of the board	Title	Age	Since
Philip Young CEO	Chief Executive Officer	66	21-01-14
Baxter Phillips COO	Chief Operating Officer	48	22-10-02
Michael Petter BRD	Director/Board Member	-	21-01-07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	79,136,172	77,238,066 ( 97.60 %)	0	97.60 %

Name	Equities	%	Valuation
Maghsoud Dariani 10.79 %	8,418,840	10.79 %	117 864 $
Michael Iain Petter 2.569 %	2,003,636	2.569 %	28 051 $
Jonathan Gilbert 2.432 %	1,896,632	2.432 %	26 553 $
Baxter Phillips 0.8719 %	680,000	0.8719 %	9 520 $
Philip Young 0.6251 %	487,500	0.6251 %	6 825 $
Brian Zasitko 0.0134 %	10,417	0.0134 %	146 $

Lobe Sciences Ltd.

1199 West Hastings Street Suite 1400

V6E 3T5, Vancouver

+949-505-5623

http://www.lobesciences.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Alternative Medicine

	1st Jan change	Capi.
LOBE SCIENCES LTD.	-20.00%	2.41M
DONG-E-E-JIAO CO.,LTD.	+37.15%	6.01B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-16.04%	4.47B
TASLY PHARMACEUTICAL GROUP CO., LTD	-11.16%	3.11B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.40%	3.01B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.12%	2.6B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+38.69%	1.85B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+1.11%	1.66B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-10.34%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B

Alternative Medicine